ATE277035T1 - Substituierte oxime und hydrazone als neurokinin antagonisten - Google Patents

Substituierte oxime und hydrazone als neurokinin antagonisten

Info

Publication number
ATE277035T1
ATE277035T1 AT99968048T AT99968048T ATE277035T1 AT E277035 T1 ATE277035 T1 AT E277035T1 AT 99968048 T AT99968048 T AT 99968048T AT 99968048 T AT99968048 T AT 99968048T AT E277035 T1 ATE277035 T1 AT E277035T1
Authority
AT
Austria
Prior art keywords
hydrazones
neurokinin antagonists
substituted oximes
oximes
substituted
Prior art date
Application number
AT99968048T
Other languages
English (en)
Inventor
Gregory A Reichard
Neng-Yang Shih
Dasong Wang
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE277035T1 publication Critical patent/ATE277035T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT99968048T 1998-12-23 1999-12-21 Substituierte oxime und hydrazone als neurokinin antagonisten ATE277035T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22031698A 1998-12-23 1998-12-23
PCT/US1999/027953 WO2000039114A2 (en) 1998-12-23 1999-12-21 Substituted oximes and hydrazones as neurokinin antagonists

Publications (1)

Publication Number Publication Date
ATE277035T1 true ATE277035T1 (de) 2004-10-15

Family

ID=22823070

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99968048T ATE277035T1 (de) 1998-12-23 1999-12-21 Substituierte oxime und hydrazone als neurokinin antagonisten

Country Status (14)

Country Link
EP (1) EP1144402B1 (de)
JP (2) JP4370059B2 (de)
CN (1) CN1414961A (de)
AR (1) AR021968A1 (de)
AT (1) ATE277035T1 (de)
AU (1) AU2474200A (de)
CA (1) CA2355886C (de)
CO (1) CO5160341A1 (de)
DE (1) DE69920516T2 (de)
ES (1) ES2226493T3 (de)
HK (1) HK1037182A1 (de)
PE (1) PE20001353A1 (de)
TW (1) TW533210B (de)
WO (1) WO2000039114A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2226493T3 (es) * 1998-12-23 2005-03-16 Schering Corporation Oximas e hidrazonas sustituidas como antagonistas de neroquinina.
US6455554B1 (en) 1999-06-07 2002-09-24 Targacept, Inc. Oxopyridinyl pharmaceutical compositions and methods for use
SI1598339T1 (sl) 2001-04-18 2009-12-31 Euro Celtique Sa Derivati 1-(4-amino.cikloheksil)-1,3-dihidro-2h-benzimidazol-2-ona in sorodne spojine kot nociceptinski analogi in ORL1 ligandi za zdravljenje bolečine
UA75425C2 (en) 2001-07-09 2006-04-17 Piperazine oxime derivatives with antagonistic activity to nk-1 receptor, use thereof, a pharmaceutical composition based thereon, a method for producing and a method for producing intermediary compounds
AR048526A1 (es) * 2004-04-07 2006-05-03 Schering Corp Antagonistas de nk1 de anillo de piperidina o pirrolidina fusionado, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades relacionadas con los receptores de neuroquinina nk1
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
GB0506800D0 (en) * 2005-04-04 2005-05-11 Merck Sharp & Dohme New uses
US8110681B2 (en) 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
US8653080B2 (en) 2009-01-14 2014-02-18 Salk Institute For Biological Studies Methods for screening and compounds that protect against amyloid diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9321557D0 (en) * 1992-11-03 1993-12-08 Zeneca Ltd Carboxamide derivatives
GB9317104D0 (en) * 1993-08-17 1993-09-29 Zeneca Ltd Therapeutic heterocycles
GB9322643D0 (en) * 1993-11-03 1993-12-22 Zeneca Ltd Lactam derivatives
US5696267A (en) * 1995-05-02 1997-12-09 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
US5688960A (en) * 1995-05-02 1997-11-18 Schering Corporation Substituted oximes, hydrazones and olefins useful as neurokinin antagonists
US5654316A (en) * 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
PE134599A1 (es) * 1997-11-21 2000-01-07 Schering Corp Oximas sustituidas como antagonistas en neuroquinina
ES2226493T3 (es) * 1998-12-23 2005-03-16 Schering Corporation Oximas e hidrazonas sustituidas como antagonistas de neroquinina.

Also Published As

Publication number Publication date
AU2474200A (en) 2000-07-31
EP1144402A2 (de) 2001-10-17
JP2002533451A (ja) 2002-10-08
TW533210B (en) 2003-05-21
EP1144402B1 (de) 2004-09-22
DE69920516T2 (de) 2005-12-01
CN1414961A (zh) 2003-04-30
PE20001353A1 (es) 2000-12-07
EP1144402A3 (de) 2002-09-11
AR021968A1 (es) 2002-09-04
ES2226493T3 (es) 2005-03-16
CA2355886A1 (en) 2000-07-06
JP4370059B2 (ja) 2009-11-25
DE69920516D1 (de) 2004-10-28
CA2355886C (en) 2006-10-31
WO2000039114A2 (en) 2000-07-06
JP2006298939A (ja) 2006-11-02
CO5160341A1 (es) 2002-05-30
HK1037182A1 (en) 2002-02-01
WO2000039114A3 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
DE69908469T2 (de) Mehrpegel-Phasentreiber und statische Stromwandler
NO20006062D0 (no) Innkapslede spaltningsstoffer, blandinger og fremgangsmåte for anvendelse derav
ATE277035T1 (de) Substituierte oxime und hydrazone als neurokinin antagonisten
DE60040036D1 (de) Toner und Entwicklerzusammensetzungen
DE69912533D1 (de) Magnetische Befestigungsvorrichtung
NO20005266L (no) Nye substituerte amider, deres fremstilling og anvendelse
ATE357443T1 (de) Dihydrobenzodioxincarbonsäureamid- und ketonderivate als 5-ht4-rezeptorantagonisten
NO20024201D0 (no) Substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-on og anvendelse derav for hemning av hormonsensitiv lipase
NO996115D0 (no) Azetidinylpropylpiperidin-derivater, intermediater og anvendelse som tachykinin-antagonister
TR199501132A2 (tr) Nörokinin karsitlari (antagonistleri).
NO20026168D0 (no) 3-azabicyklo(3.1.0)heksan derivater med opioid reseptor affinitet
NO20003261D0 (no) Blandinger avledet fra Mycobacterium vaccae og fremgangsmÕter for deres anvendelse
DE60010346D1 (de) Als überzüge verwendbare witterungsbeständige zusammensetzungen, verfahren, und damit überzogene artikel
DE69917451D1 (de) Sulfonylbenzolverbindungen als analgetische und entzündungshemmende mittel
PT1044916E (pt) Porta-bobinas
DE19983695T1 (de) Schaltkreissynthese und -verifizierung unter Berücksichtigung des relativen Zeitverhaltens
NO20022564L (no) Nye androgener
DE60019950D1 (de) Verriegelungsanordnung für eine ausgangstür
NO20030220L (no) Ny form av (R)-N-[5-metyl-8-(4-metylpiperazin-1-yl)-1,2,3,4- tetrahydro-2-naftyl]-4-morfolinobenzamid
ITUD20000182A0 (it) Dispositivo per chiudere ed aprire rapidamente e selettivamente i valichi di servizio (by-pass) nello spartitraffico centrale di un'autostr
ATE259355T1 (de) Substituierte oxime als neurokinin antagonisten
EP1539679A4 (de) Oxim- und/oder hydrazonhaltige, nitrosierte und/oder nitrosylierte cyclooxigenase-2-selektive inhibitoren, zusammensetzungen und anwendungsverfahren
DE60327928D1 (de) Herstellung von homopolymeren, copolymeren und terpolymeren aus substituierten styrolen
NO20014467D0 (no) Tjoringsapparat og en treghetslåsespole
NO20015068L (no) Nye 8A- og 9A-15-ringlaktamer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties